in patients with STEMI independent of diabetes mellitus and the safety/tolerability of this drug in an acute setting. To establish these issues, we conducted serial assessment of cardiac biomarkers, routine and speckle tracking echocardiography, and cardiac magnetic resonance imaging in patients with STEMI after performing primary percutaneous coronary intervention (pPCI).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Patient Characteristics
Between September 2009 and August 2011, we assessed eligibility for 127 consecutive patients with STEMI meeting the clinical eligibility criteria (Figure 1 ). Eleven patients were excluded from the study before randomization as a withdrawal of consent. After randomization, patients with impaired left ventricular (LV) systolic function (n=18), patients with thrombolysis in myocardial infarction flow grade 1, 2 or 3 on angiography (n=40) were also excluded. All remaining 58 patients completed the study protocol by performing the cardiac magnetic resonance study. No patients performed direct stenting, distal protecting devices, or glycoprotein IIb/IIIa administration. Successful PCI with drug-eluting stents was performed in all patients, and complete revascularization was achieved at a rate of 88%. During the 6-month follow-up, no clinical event, including death, reinfarction, stroke, and unplanned revascularization, happened. Table 1 shows the baseline angiographic and procedural results for all randomized patients and for the patients included in the study. The study groups were well balanced.
Biomarkers, Cardiac Magnetic Resonance, and Echocardiographic Results
Patients included in the study had significantly higher area under the concentration of creatine kinase-MB (12065±6245 versus 10412±6725 arbitrary units; P=0.01) and troponin I (5739±3106 versus 2429±3525; P=0.01) than excluded patients. In included patients, exenatide treatment significantly reduced the area under the concentration of creatine kinase-MB (9658±6219 versus 13149±6021; P=0.04; Figure 2A ) and troponin I (3181±2924 versus 6890±2449; P<0.001; Figure 2B ) release. In randomized patients, significant reduction of creatine kinase-MB (7879±6173 versus 9482±6094; P=0.01; Figure 2C ) and troponin I (1884±2144 versus 3143±2015; P=0.01; Figure 2D ) could be noted in exenatide group.
Cardiac magnetic resonance was performed 38±7 days after pPCI. Figure 3 demonstrates examples from exenatide and control group. Infarct size ( Figure 4A ) and the absolute mass of the infarcted area ( Figure 4B ) were significantly decreased in the exenatide group.
At admission, the levels of high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide were similar in the exenatide and control groups (Table 1) . At 1-month follow-up, baseline-adjusted levels of hs-CRP were significantly decreased in the exenatide group (1.1±0.4 versus 2.7±0.3 mg/L; P<0.001), but N-terminal pro-Btype natriuretic peptide did not show significant difference (96.7±13.1 versus 106.0±8.8 pg/mL; P=0.53). To investigate the effect of exenatide on reducing hs-CRP levels, the reduction rate of hs-CRP<3.0 mg/L was evaluated. At 1-month follow-up, exenatide treatment was associated with reduction of hs-CRP<3.0 mg/L (exenatide: from 7 [39%] to 2 [11%]; control: from 20 [50%] to 14 [35%]; P=0.04). In multivariate analysis adjusting concomitant medications, adjunctive exenatide therapy was independently associated with reduction of hs-CRP levels (hazard ratio, 2.55 [95% confidential interval, 1.29-4.07]; P=0.03). Table 2 shows the results of serial routine and speckle tracking echocardiography in the exenatide and control groups. At initial presentation, all routine and speckle tracking parameters were similar in both groups. Three days after pPCI, there was no significant difference in LV ejection fraction (EF) and wall motion score index. However, the exenatide group showed significantly higher absolute values of global longitudinal ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OHA, oral hypoglycemic agent; and RCA, right coronary artery. strain (GLS) and GLS rate (GLSR). At 6-month follow-up after pPCI, both groups exhibited significant improvement in LV EF and wall motion score index compared with baseline. Exenatide group showed significantly higher LV EF and lower E/E′ compared with control group. In addition, the absolute values of GLS, GLSR, and global circumferential strain significantly improved and showed a significant difference in exenatide group.
Although these are small numbers of patients, we evaluated the possibility of influence of diabetes mellitus or culprit artery difference on cardioprotective effect of exenatide treatment ( Figure I in the online-only Data Supplement). Prominent cardioprotective effects in patients with diabetes mellitus and anterior myocardial infarction could be observed.
Safety and Tolerability
During the study period, no patient refused the study drug, exenatide or placebo. Although there were significant differences of blood pressure at 48 hours after randomization, exenatide treatment did not contribute to develop new onset hypertension. As shown in Table 3 , 1 patient in the exenatide group experienced symptomatic hypoglycemia at 3 days of exenatide therapy. He had sulfonylurea concomitantly and serum glucose was 70 mg/dL at that time. By glucose infusion, he was able to complete the study period. In the control group, 1 patient who was treated with insulin experienced hypoglycemia and adjustment of insulin was performed. Nausea, vomiting, and loss of appetite were common adverse effects in the exenatide group. No kidney function impairment, chest pain aggravation, and new onset dyspnea were detected in the exenatide group (Table 4 ).
Reproducibility
To determine the reproducibility of the echocardiographic parameters, 20 randomly selected patients were analyzed by 2 independent blinded observers as we previously described. 9 The correlation coefficients of interobserver variability for LV EF, wall motion score index, GLS, GLSR, global circumferential strain, and global radial strain were 0.94, 0.95, 0.97, 0.96, 0.94, and 0.93, respectively. For intraobserver variability, the same observer measured echocardiographic data for each of the selected patients again 30 days later. The correlation coefficients of intraobserver variability for LV EF, wall motion score index, GLS, GLSR, global circumferential strain, and global radial strain were 0.92, 0.96, 0.97, 0.98, 0.94, and 0.94, respectively.
Discussion
Infarct size is an important determinant of cardiovascular outcome, including death, reinfarction, and congestive heart failure. Administration of exenatide was associated with a reduction in infarct size of ≈40%, as postconditioning by PCI. 10 With infarct size reduction, the GLS and GLSR, thought as a more sensitive index of systolic function, 9, 11 were significantly improved at 3 days and global circumferential strain at 6 months after pPCI in the exenatide group. Impressively, patients with exenatide did not develop increased LV filling pressure (E/E′>15) at 6-month follow-up. We also observed exenatide treatment showed significant reduction of hs-CRP level at 1 month. During myocardial infarction or ischemia, an upward shift in the pressure-volume curve was seen as a result of an increase in resistance to LV filling or increased chamber stiffness. 12 The increased LV filling pressure has been known as a predictor of increasing cardiovascular risks, such that they poorly adapt to the hemodynamic changes during acute myocardial ischemia and poorly tolerate an acute loss of even relatively small amount of myocardium. 13 By reduction of systemic inflammation and infarct size, exenatide could improve diastolic function, early phase of ischemic cascade, with decreasing cardiovascular burden of risk.
The mechanisms underlying this cardioprotective effect are complex. By increasing myocardial glucose uptake, more efficient adenosine triphosphate could be generated which might, therefore, reduce oxygen demand compared with free fatty acids during ischemia. 14 In addition to its beneficial metabolic effects, GLP-1 could have postconditioning mimicking effects. Like adenosine, nicorandil, and opioids, GLP-1 can trigger molecules for initiating survival pathways in ischemic/reperfusion injuries. 15, 16 GLP-1 promotes activation of phosphatidylinositol 3 kinase, serine-threonine kinase (Akt), Mean values and SD of 3-day and 6-month follow-up echocardiographic data are presented as adjusted results by ANCOVA. EDV indicates end-diastolic volume; ESV, end-systolic volume; LV, left ventricular; and WMSI, wall motion score index. *P<0.05; P value was analyzed between exenatide and control group.
mitogen-activated protein kinase (MEK 1/2), and extracellular signal-regulated kinase (ERK 1/2), which are distal targets of G protein-coupled receptor activation. 16 The phosphatidylinositol 3 kinase/Akt pathway triggers endothelial nitric oxide synthase, which is important to cardioprotection by postconditioning. 17, 18 Activation of phosphatidylinositol 3 kinase also leads to downstream phosphorylation and inhibition of the proapoptotic protein Bcl-xL/Bcl-2-associated death promoter (BAD). 19 Activation of these signaling pathways involves 2 targets: opening of the mitochondrial K ATP channels 19, 20 and preventing the opening of mitochondrial permeability transition pores (mPTP). 19 By opening of K ATP channels and preventing the opening of mitochondrial permeability transition pores, GLP-1 could have a pivotal role in preserving mitochondrial function after ischemia/reperfusion injuries. GLP-1 also stimulates phospholipase C and the generation of inositol triphosphate and diacyglycerol, the latter of which stimulates protein kinase C. Protein kinase C is also a key signaling pathway in cardioprotection. 21 With reducing myocardial apoptosis and oxidative stress, exenatide might have an anti-inflammatory effect during ischemia/reperfusion injuries. 4 By acting on GLP-1 receptors, exenatide may provide cardioprotective effects through several pathways associated with metabolism, contractility, reduction of apoptotic cell death, and anti-inflammatory effect. Interest in the cardioprotective effects of exenatide has increased because of various reports with evidence. [2] [3] [4] [5] [6] [7] In patients with STEMI with single-vessel disease, 6-hour continuous infusion of exenatide (25 μg) before and after pPCI was associated with the improvement of myocardial salvage. 6 Their post hoc analysis 8 showed exenatide treatment was associated with a 30% decrease in final infarct size in patients with short system delay (≤132 minutes). In addition, Bernink et al 22 reported that 5 μg loading and 72-hour continuous intravenous infusion (20 μg/24 hours) of exenatide showed a trend toward a smaller infarction size but not significant difference. One important difference compared with previous studies is administrating dose and route of exenatide. High-dose exenatide would yield a larger cardioprotective effect. However, safety and feasibility of high-dose exenatide should be considered. The clinical use of exenatide is 10 μg twice daily via subcutaneous injections for treatment of patients with diabetes mellitus. This study was a safety/pilot/phase I study to investigate that routine use of exenatide could have cardioprotective effects in patients with STEMI. Because myocardial ischemia-reperfusion injury occurs in the first few minutes of coronary artery reperfusion, exenatide was administered before the restoration of blood flow with higher dose during the reperfusion therapy. By a hybrid form of exenatide administration, that is, higher bolus and continued routine use, this study showed significant reduction of myocardial infarct size in patients with STEMI with single and multivessel diseases. In addition, the present study demonstrated short-term exenatide therapy was associated with improvement of diastolic function and strain parameters at 6-month follow-up. In subgroup analysis, exenatide therapy is associated with more reduction of infarct size in patients with diabetes mellitus and anterior myocardial infarction than in non-diabetes mellitus or nonanterior myocardial infarction. The small study population could also contribute to these discrepancies, but one of the postulated mechanisms is that the action of GLP-1 may be different according to plasma glucose status. In isolated normal rat hearts, GLP-1 resulted in increased plasma insulin levels, and associated phosphorylation and activation of Akt led to GLUT-4 translocation. 14 Under hyperglycemic circumstances, the insulinotropic actions of GLP-1 to stimulate pancreatic insulin release predominate over the insulinomimetic effects seen under euglycemic conditions. 17 This metabolic benefit would also contribute to the difference according to infarct-related artery but further studies are needed.
In concordance with previous reports, exenatide treatment was associated with gastrointestinal symptoms, particularly nausea and vomiting. 18 The sensation of nausea with exenatide use is thought to be because of slowed gastric emptying, appetite suppression, or stimulation of neural GLP-1 receptors. However, these gastrointestinal-related adverse events did not lead to discontinuation of the study and disappeared after the 3-day study period. Careful attention is needed to avoid hypoglycemia in patients taking sulfonylurea or insulin concomitantly.
A major limitation was the small study population. Although this study was performed as a proof-of-concept trial, selection bias could not be totally excluded. In addition, this study was not a double-blind randomized trial because of technical problem. Because of the recommendation from Institutional Clinical Research and Ethics Committee, we could not enroll patients with systolic dysfunction after STEMI. Larger randomized trials with clinically hard end points, such as cardiovascular morbidity and mortality, will be needed to conclusively establish the benefits of acute-phase adjunctive exenatide theapy over standard therapy. In addition, we could not provide metabolic properties of exenatide because we did not measure metabolic data except glucose during follow-up period. Finally, we could not assess the GLP-1 levels during study period to identify the blood concentration levels protecting myocardium and the mechanism of decreased hs-CRP levels in the exenatide group.
In conclusion, adjunctive exenatide theapy in acute phase may reduce myocardial infarct size and improve subclinical LV systolic function with reasonable safety/tolerability.
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